| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
122,563,000 |
| Market
Cap: |
5.92(B) |
| Last
Volume: |
8,264,325 |
Avg
Vol: |
8,241,683 |
| 52
Week Range: |
$26.88 - $108.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
91,318 |
237,059 |
410,079 |
888,401 |
| Total Sell Value |
$6,319,460 |
$16,812,843 |
$22,688,654 |
$44,103,545 |
| Total People Sold |
2 |
4 |
5 |
11 |
| Total Sell Transactions |
4 |
16 |
36 |
82 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Callos Andrew |
EVP, Chief Commercial Officer |
• – – |
2022-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
26,196 |
|
- |
|
| Wong Robert |
VP, Chief Accounting Officer |
• – – |
2022-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
33,344 |
|
- |
|
| Wong Robert |
VP, Chief Accounting Officer |
• – – |
2022-03-02 |
4 |
D |
$37.63 |
$54,451 |
D/D |
(1,447) |
25,844 |
|
- |
|
| Schlossberg Mark A |
SVP - Legal & General Counsel |
• – – |
2022-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
72,418 |
|
- |
|
| Schlossberg Mark A |
SVP - Legal & General Counsel |
• – – |
2022-03-02 |
4 |
D |
$37.63 |
$130,087 |
D/D |
(3,457) |
52,418 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2022-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
178,000 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2022-03-02 |
4 |
D |
$37.63 |
$188,301 |
D/D |
(5,004) |
148,000 |
|
- |
|
| Cragg David |
Chief HR & Admin Officer |
• – – |
2022-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
158,632 |
|
- |
|
| Cragg David |
Chief HR & Admin Officer |
• – – |
2022-03-02 |
4 |
D |
$37.63 |
$130,125 |
D/D |
(3,458) |
138,632 |
|
- |
|
| Jaw Ching |
SVP Finance & CFO |
• – – |
2022-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
72,619 |
|
- |
|
| Jaw Ching |
SVP Finance & CFO |
• – – |
2022-03-02 |
4 |
D |
$37.63 |
$130,125 |
D/D |
(3,458) |
52,619 |
|
- |
|
| Costa Santo J |
Director |
– • – |
2022-03-02 |
4 |
S |
$37.35 |
$373,477 |
D/D |
(10,000) |
5,000 |
|
-19% |
|
| Costa Santo J |
Director |
– • – |
2022-03-02 |
4 |
OE |
$10.68 |
$106,800 |
D/D |
10,000 |
15,000 |
|
- |
|
| Henderson John T |
Director |
– • – |
2022-03-01 |
4 |
OE |
$5.46 |
$22,746 |
D/D |
4,166 |
18,074 |
|
- |
|
| Jaw Ching |
SVP Finance & CFO |
• – – |
2022-02-28 |
4 |
D |
$35.32 |
$73,254 |
D/D |
(2,074) |
56,077 |
|
- |
|
| Cragg David |
Chief HR & Admin Officer |
• – – |
2022-02-28 |
4 |
D |
$35.32 |
$73,148 |
D/D |
(2,071) |
142,090 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2022-02-28 |
4 |
D |
$35.32 |
$400,140 |
D/D |
(11,329) |
363,789 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2022-02-28 |
4 |
D |
$35.32 |
$122,137 |
D/D |
(3,458) |
153,004 |
|
- |
|
| Wong Robert |
VP, Chief Accounting Officer |
• – – |
2022-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,987 |
27,291 |
|
- |
|
| Callos Andrew |
EVP, Chief Commercial Officer |
• – – |
2022-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
5,044 |
6,196 |
|
- |
|
| Schlossberg Mark A |
SVP - Legal & General Counsel |
• – – |
2022-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
5,025 |
55,875 |
|
- |
|
| Cragg David |
Chief HR & Admin Officer |
• – – |
2022-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
5,008 |
144,161 |
|
- |
|
| Malik Fady Ibraham |
EVP Research & Development |
• – – |
2022-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,148 |
156,462 |
|
- |
|
| Jaw Ching |
SVP Finance & CFO |
• – – |
2022-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
5,022 |
58,151 |
|
- |
|
| Blum Robert I |
President & CEO |
• • – |
2022-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
14,474 |
375,118 |
|
- |
|
710 Records found
|
|
Page 12 of 29 |
|
|
0.68 (1.39%) 
